LEADER 05245nam 2200661Ia 450 001 9910954395803321 005 20251116215332.0 010 $a0-309-18061-9 010 $a1-280-70492-6 010 $a9786610704927 010 $a0-309-65814-4 035 $a(CKB)1000000000469281 035 $a(OCoLC)560385115 035 $a(CaPaEBR)ebrary10150106 035 $a(SSID)ssj0000137700 035 $a(PQKBManifestationID)11130061 035 $a(PQKBTitleCode)TC0000137700 035 $a(PQKBWorkID)10088698 035 $a(PQKB)11501473 035 $a(MiAaPQ)EBC3378153 035 $a(Au-PeEL)EBL3378153 035 $a(CaPaEBR)ebr10150106 035 $a(CaONFJC)MIL70492 035 $a(OCoLC)923277128 035 $a(BIP)53856375 035 $a(BIP)13662591 035 $a(EXLCZ)991000000000469281 100 $a20060807d2006 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 10$aDeveloping biomarker-based tools for cancer screening, diagnosis, and treatment $ethe state of the science, evaluation, implementation, and economics /$fMargie Patlak and Sharyl Nass, rapporteurs ; National Cancer Policy Forum 205 $a1st ed. 210 $aWashington, DC $cNational Academies Press$dc2006 215 $a1 online resource (112 p.) 300 $aBibliographic Level Mode of Issuance: Monograph 311 08$a0-309-10134-4 320 $aIncludes bibliographical references. 327 $aFrontmatter -- Reviewers -- Contents -- Introduction -- Overview of Technologies Used to Discover Cancer Biomarkers -- Meeting the Technical Challenges of Biomarker Validation and Qualification -- Coordinating the Development of Biomarkers and Targeted Therapies -- Biomarker Development and Regulatory Oversight -- Assessment and Adoption of Biomarker-Based Technologies -- Economic Impact of Biomarkers -- Clinical Development Strategies for Biomarker Utilization Discussion -- Strategies for Implementing Standardized Biorepositories Discussion -- Strategies for Determining Analytic Validity and Clinical Utility of Biomarkers Discussion -- Strategies to Develop Biomarkers for Early Detection Discussion -- Mechanisms for Developing an Evidence Base Discussion -- Evaluation of Evidence in Decision Making Discussion -- Incorporating Biomarker Evidence Into Clinical Practice Discussion -- Acronyms -- Glossary -- References -- Appendixes -- Appendix A Workshop Agenda -- Appendix B Workshop Speakers, Moderators, Invited Discussants, and Participants. 330 $aResearch has long sought to identify biomarkers that could detect cancer at an early stage, or predict the optimal cancer therapy for specific patients. Fueling interest in this research are recent technological advances in genomics, proteomics, and metabolomics that can enable researchers to capture the molecular fingerprints of specific cancers and fine-tune their classification according to the molecular defects they harbor. The discovery and development of new markers of cancer could potentially improve cancer screening, diagnosis, and treatment. Given the potential impact cancer biomarkers could have on the cost effectiveness of cancer detection and treatment, they could profoundly alter the economic burden of cancer as well. Despite the promise of cancer biomarkers, few biomarker-based cancer tests have entered the market, and the translation of research findings on cancer biomarkers into clinically useful tests seems to be lagging. This is perhaps not surprising given the technical, financial, regulatory, and social challenges linked to the discovery, development, validation, and incorporation of biomarker tests into clinical practice. To explore those challenges and ways to overcome them, the National Cancer Policy Forum held the conference "Developing Biomarker-Based Tools for Cancer Screening, Diagnosis and Treatment: The State of the Science, Evaluation, Implementation, and Economics" in Washington, D.C., from March 20 to 22, 2006. At this conference, experts gave presentations in one of six sessions. In addition, seven small group discussions explored the policy implications surrounding biomarker development and adoption into clinical practice. Developing Biomarker-based Tools for Developing Cancer Screening, Diagnosis, and Treatment: The State of the Science, Evaluation, Implementation, and Economics-Workshop Summary presents the conference proceedings and will be used by an Institute of Medicine (IOM) committee to develop consensus-based recommendations for moving the field of cancer biomarkers forward. 606 $aTumor markers$vCongresses 606 $aBiochemical markers$vCongresses 615 0$aTumor markers 615 0$aBiochemical markers 676 $a616.99/4075 700 $aPatlak$b Margie$01607028 701 $aNass$b Sharyl J$0857626 712 02$aNational Cancer Policy Forum (U.S.) 712 02$aUnited States.$bDept. of Health and Human Services. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910954395803321 996 $aDeveloping biomarker-based tools for cancer screening, diagnosis, and treatment$94475233 997 $aUNINA